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Background
OCD with an onset in childhood or early adolescents is
usually presented as a specific subtype, with more boys
affected and frequently co-morbid with tics and Tourette's
syndrome [1]. Our observation in clinical practice indi-
cates that during the pharmacotherapy the OCD and
Tourette's syndromes shift continuously. As a result for
successful treatment medication should be changed from
SSRIs to antipsychotic with dopaminolitic properties or a
combination of both is needed.
Materials and methods
In open studies we conducted an 8-week trial of 14 ado-
lescents (12-15 year old, 9 male and 5 female) with co-
morbid OCD and Tourette's syndrome. All patients had
been pretreated for several years with a number of psycho-
tropic medications including haloperidole, sulpiride, ser-
traline, fluvoxamine and clomipramine. Before starting
the study all patients passed a 2-week drug washout
period. All patients were diagnosed according to DSM-4
criteria of OCD and ICD -10 criteria of tic disorders. Also
patients held CY-BOCS and Zung tests for depression and
CGI-TS-S. Dosage range of Geodon was from 20 to 80-140
mg./day depending on the effectiveness.
Results
Despite the fact that the treatment began with 20 mg of
ziprasidon, no patient showed improvement, and even 40
mg of Geodon did not help. In 6 patients we observed
improvement of OCD syndrome (CY-BOCS scores 28 %
mean degrease from baseline) with a dosage between 60-
80 mg (60 + 20 mg capsule in bed time). Among 9 adoles-
cents we observed much improvement of both symptoms
after 4 week treatment with a dosage from 80 to 120-140
mg. (CGI -TS Severity baseline 4,5 +− 0,6 endpoint 2,6 +−
1,2)
Conclusions
Taking into consideration the fact that co-morbid OCD
and Tourette's syndrome are treated successfully by medi-
cations with different mechanisms of neuronal action, the
studies of athipical antipsychotics with both dopamine
and serotonine properties are promising. Consequently,
the atypical antipsychotic with dopamine and serotonin
properties possibly can be the most useful medication.
However, a new control study with a larger target group is
needed.
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